 |
January 15, 2025 |
|
Dear Advocate,
Welcome to January 2025! This update shares new resources to keep you informed and inspired in the fight for choice, science, equity and sustainability in the HIV response in 2025 and beyond.
|
| New Podcast Episode Alert! |
|
|
| |
| Revisit Our Episode on HIV Prevention and the US Administration |
|
|
| |
|
|
 |
As the US prepares this week for its presidential inauguration and confirmation hearings for Cabinet nominees, it’s a great time to listen to KFF’s Jen Kates and AVAC’s Suraj Madoori lay out the challenges and the priorities in 2025 and beyond. In the days, months and years ahead, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention and in global health generally. It’s imperative to understand the implications for the global AIDS response, and to safeguard policies and programs that advance it.
|
|
|
|
|
|
|
| March 5, 2025 I 12:00 - 1:30pm EST |
|
|
|
 |
Advancing Clinician Support in the United States Through a Unique Distance-Based Model
Join the TCA and the National Clinician Consultation Center (NCCC) for a webinar featuring NCCC’s innovative, cost-free teleconsultation program, which provide a free, real-time, expert guidance on HIV, viral hepatitis, and substance use to clinicians across the US, regardless of location or clinical setting. Participants will discuss this model and strategies to adapt it for global healthcare challenges.
|
|
|
|
|
| Navigating the PrEP Landscape |
|
|
| |
With a growing number of PrEP options in, or soon in the market, and others in advanced development, and an increase in PrEP initiations worldwide, the future of PrEP has never been more exciting – and challenging.
|
 |
|
|
Global PrEP Tracker
AVAC’s interactive Global PrEP Tracker provides up-to-date information on PrEP initiations by country and delivery model, offering insights into the progress and impact of PrEP programs around the world.
|
|
|
|
|
|
 |
|
|
Opinion: The world has a new HIV prevention drug. Let’s use it
A new op-ed by Jirair Ratevosian and Mitchell Warren in Devex discusses the potential of lenacapavir, an every six-month injectable pre-exposure prophylaxis (PrEP) medication, to transform the HIV response, but only if it is rolled out with speed, scale and equity.
|
|
|
|
|
|
As we navigate an uncertain political landscape and embrace the promise of innovative PrEP products, advocacy will remain our most powerful tool.
|
|
|
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences | Unsubscribe
|
|
|
